Table 5.
Association between hydrophilic of statins and first-time sarcopenia among CKD patients in Taiwan.
| Variable | Crude Sarcopenia HR (95% CI) |
p Trend | Adjust Sarcopenia HR (95% CI) |
p Value |
|---|---|---|---|---|
| Statin Non-user (<28 cDDDs) | 1 | 1 | ||
| Hydrophilic Statin User | 0.895 (0.735–1.090) | 0.2706 | 1.013 (0.826–1.241) | 0.9046 |
| Hydrophilic Statin use level * | 0.015 | 0.0283 | ||
| 28–89cDDDs | 1.275 (0.960–1.692) | 1.404 (1.053–1.870) | ||
| 90–180cDDDs | 0.827 (0.583–1.720) | 0.933 (0.655–1.327) | ||
| >180cDDDs | 0.589 (0.391–0.889) | 0.684 (0.452–1.036) |
* Statin use and categorization was defined by cumulative prescription (cDDDs) of statin. Models adjusted gender, age, income, urbanization, comorbidity.